The old adage hold true. Thanks IDRA mgt. for NOTHING! Luckily their options will now be worth that also. Only sad part is their fat salaries for returning nothing to the shareholders.
Still here also. Very trying to not bail. This is the only bio that is in the red in my portfolios. And in the red it is. Looking now... One down 66%. Another down 63% and the third down 27%. VERY discouraging! Hope someone has a plan at the company.
Thanks for sharing. Very good find.
One has to think the stock will jump big next week.
SAN DIEGO, April 11, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an Agreement with Stratose, Inc., establishing in-network health plan access to Trovagene's suite of Precision Cancer Monitoring(R) (PCM) tests and services. Stratose maintains one of the largest directly managed PPO networks in the U.S., administering health benefits for more than 8.6 million covered lives.
AH is already getting hammered with the firings. Going to be UGLY tomorrow.
Here is the story:
"Idera Pharmaceuticals (IDRA - Get Report) , a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of therapeutics for oncology and rare diseases in the U.S. This stock traded up 13.5% to $2.10 in Friday's trading session.
From a technical perspective, Idera Pharmaceuticals exploded sharply higher on Friday right off its 50-day moving average of $1.90 a share with strong upside volume flows. This high-volume rip to the upside has now pushed shares of Idera Pharmaceuticals into breakout territory, after the stock closed above some near-term overhead resistance at $2.08 a share. This move is now starting to push this stock within range of triggering another breakout trade. That trade will trigger if this stock manages to take out Friday's intraday high of $2.14 a share to some more key near-term resistance levels at $2.25 to around $2.40 a share with high volume.
Traders should now look for long-biased trades in Idera Pharmaceuticals as long as it's trending above its 50-day moving average of $1.90 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.13 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.60 to its 200-day moving average of $2.96, or even $3.20 a share."
Still nice to see him buy on the open market. Better than options. Shows confidence IMO.
Just came out now. I can't download. Can anyone view?